Bristol-Myers Squibb (BMY) and Janssen Biotech (JNJ) will collaborate in a Phase 2 clinical trial evaluating the combination of BMY's Opdivo (nivolumab) and Janssen's immunotherapy JNJ-64041757 in patients with non-small cell lung cancer (NSCLC). JNJ-64041757 is an antigen-presentation therapeutic based on Live Attenuated Double-Deleted Listeria monocytogenes bacteria strains engineered to induce an immune response against NSCLC tumors. It is currently in Phase 1 development for lung cancer.